Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at 29th Annual Roth Conference
Moleculin Biotech (NASDAQ: MBRX) is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukaemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas. For more information, visit the company’s website at www.moleculin.com.…







